Definitions
Sorry, no definitions found. You may find more data at diovan.
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word Diovan.
Examples
-
Analysts will focus on the effect of the gradual patent expiries of cancer drug Femara and heart medicine Diovan, which is expected to accelerate later this year.
Novartis Is Expected to Outpace Peers Goran Mijuk 2011
-
Sales of Diovan, which is facing increased competition from the generic version of Merck
Yahoo! News: Latest news headlines News Headlines | Top Stories 2010
-
No day to day side effects, except that I have exercise induced asthma, and I don't know if the Diovan is the cause of that at all.
-
Sales of Diovan, which is facing increased competition from the generic version of Merck
Yahoo! News: Latest news headlines News Headlines | Top Stories 2010
-
Novartis, meanwhile, faces the patent loss of its key heart drug Diovan, which has annual sales of more than $6 billion, and cancer medicine Femara, which nets more than $1 billion in revenue each year.
Drug Makers Expect Tough 2011 Sten Stovall 2011
-
Other strong performers included diabetes drug Galvus and high blood pressure treatment Exforge, which helped Novartis balance the partial patent loss of heart medicine Diovan and cancer medicine Femara.
Eye Care Boosts Novartis Goran Mijuk 2011
-
He notes that by 2012 the bigger products will have gone, like Pfizer 's Lipitor, Sanofi 's and Bristol-Meyer Squibb 's Plavix, and Novartis ' Diovan.
Pharma Edges Toward 'Patent Cliff' Sten Stovall 2011
-
"We see Novartis bucking the trend of generic dilution given its ability to replace ... blockbusters such as heart drug Diovan and cancer medicine Gleevec with innovative products such as Gilenya, [blood-pressure drug] Tekturna and [cancer medicine] Tasigna," Nomura analyst Amit Roy said.
Novartis Seen Gaining as Merck Scraps MS Drug Goran Mijuk 2011
-
The Swiss drug maker, which is trying to balance the sales decline stemming from the expiration of its blockbuster heart drug Diovan, issued the cautious 2012 earnings outlook as it reported a 47% drop in fourth-quarter net profit.
Novartis Issues Cautious View for 2012 Sten Stovall 2012
-
The revenue increase came despite the company's two blockbuster products, Diovan and cancer medicine Femara, being hit hard by competition from generic drugs.
Novartis Issues Cautious View for 2012 Sten Stovall 2012
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.